Department of Radiology, Papa Giovanni XXIII Hospital, Bergamo, Italia.
School of Medicine, University of Milano-Bicocca, Milano, Italia.
Int J Hyperthermia. 2023;40(1):2244706. doi: 10.1080/02656736.2023.2244706.
To report procedural data and outcomes of a novel image guidance technique, CT renal arteriography (CTRA), performed to target and ablate small intraparenchymal renal tumors.
We retrospectively analyzed data of 2 patients undergoing CTRA-guided ablation for 3 renal intraparenchymal tumors, from February to March 2023. We previously evaluated tumor visibility with US/CEUS, and in all cases conspicuity was poor, whereas contrast-enhanced CT (CECT) clearly depicted all hypervascular nodules. Our primary endpoint was CTRA-guidance feasibility for renal ablation, defined as the precise probe deployment inside the target tumor. The secondary endpoint was CTRA-guided ablation technical success, intended as the inclusion of the whole tumor inside the necrotic volume, with 5 mm safety margins. RENAL scores, complications, procedural time, dose length product (DLP), serum creatinine variation and hospital stay length were also recorded.
A confident deployment of the probe tip inside the nodule was accomplished in all 3 cases, with a 100% of correct targeting. We observed immediate technical success after all 3 ablations. The 3 nodules had a RENAL score <7 points, and we encountered no complications due to line placement or ablation. The average time from preablative to postablative CTRA was 54 min (50-58min), with a DLP of 3632mGycm (2807-4458mGycm). Serum creatinine didn't show a significant variation after the procedures; both patients were hospitalized for 2 days.
Preliminary data showed that CTRA-guidance might provide unique advantages over conventional CECT-guidance to assist the ablation of small renal intraparenchymal tumor not visualized on US/CEUS.
报告一种新的图像引导技术(CT 肾动脉造影术,CTRA)在靶向和消融小的肾实质内肿瘤方面的操作数据和结果。
我们回顾性分析了 2023 年 2 月至 3 月期间 2 例因 3 个肾实质内肿瘤而行 CTRA 引导下消融术的患者数据。我们之前用 US/CEUS 评估了肿瘤的可视性,在所有情况下,肿瘤的可视性均较差,而增强 CT(CECT)则可清晰显示所有富血管性结节。我们的主要终点是 CTRA 引导下的肾消融术的可行性,定义为将探针准确地部署在目标肿瘤内。次要终点是 CTRA 引导下的消融术技术成功,即包括整个肿瘤在内的坏死体积,有 5mm 的安全边界。还记录了 RENAL 评分、并发症、操作时间、剂量长度乘积(DLP)、血清肌酐变化和住院时间。
在所有 3 例患者中,均成功将探针尖端准确地部署在结节内,实现了 100%的正确靶向。在所有 3 例消融术后,均立即获得了技术成功。3 个结节的 RENAL 评分均<7 分,且我们未遇到因置管或消融引起的并发症。从术前到术后 CTRA 的平均时间为 54 分钟(50-58 分钟),DLP 为 3632mGycm(2807-4458mGycm)。术后血清肌酐无明显变化;两名患者均住院 2 天。
初步数据表明,与传统的 CECT 引导相比,CTRA 引导可能为消融 US/CEUS 无法显示的小肾实质内肿瘤提供独特的优势。